Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
AP Lea, D McTavish - Drugs, 1997 - Springer
Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia
HS Malhotra, KL Goa - Drugs, 2001 - Springer
Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor
DM Black, RG Bakker-Arkema… - Archives of internal …, 1998 - jamanetwork.com
Background Statins (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase
inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol …
inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol …
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
JW Nawrocki, SR Weiss, MH Davidson… - … , and vascular biology, 1995 - Am Heart Assoc
Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …
Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
GL Plosker, D McTavish - Drugs, 1995 - Springer
Simvastatin is an HMG-CoA reductase inhibitor used in the treatment of patients with
hypercholesterolaemia. Since the time simvastatin was previously reviewed in Drugs, a …
hypercholesterolaemia. Since the time simvastatin was previously reviewed in Drugs, a …
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients
CB Newman, G Palmer, H Silbershatz… - The American journal of …, 2003 - Elsevier
This analysis assessed the safety of atorvastatin in the 10-to 80-mg dose range using
pooled data from 44 completed trials comprising 16,495 dyslipidemic patients treated with …
pooled data from 44 completed trials comprising 16,495 dyslipidemic patients treated with …
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease
DG Karalis, AM Ross, RM Vacari, H Zarren… - The American journal of …, 2002 - Elsevier
The efficacy and safety of atorvastatin 10 mg versus simvastatin 20 mg and atorvastatin 80
mg versus simvastatin 80 mg was determined in a 6-week, prospective, randomized, open …
mg versus simvastatin 80 mg was determined in a 6-week, prospective, randomized, open …
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
S Bertolini, GB Bon, LM Campbell, M Farnier, J Langan… - Atherosclerosis, 1997 - Elsevier
Plasma cholesterol and other lipoproteins play a significant role in the development of
atherosclerosis and subsequent coronary heart disease (CHD). This 1 year study was …
atherosclerosis and subsequent coronary heart disease (CHD). This 1 year study was …
Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
PA Todd, KL Goa - Drugs, 1990 - Springer
Synopsis Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts
by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) …
by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) …
Clinical pharmacokinetics of atorvastatin
H Lennernäs - Clinical pharmacokinetics, 2003 - Springer
Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …
相关搜索
- hmg coa ldl cholesterol
- reductase inhibitor ldl cholesterol
- hmg coa reductase inhibitor
- primary hypercholesterolemia ldl cholesterol
- hmg coa atorvastatin lipitor
- hmg coa primary hypercholesterolemia
- reductase inhibitor atorvastatin lipitor
- reductase inhibitor primary hypercholesterolemia
- hmg coa safety profile
- reductase inhibitor safety profile
- atorvastatin and simvastatin patients with dyslipidemia
- safety of atorvastatin patients with hypercholesterolemia
- comparison of efficacy simvastatin in patients
- heart disease simvastatin in patients
- efficacy and safety patients with dyslipidemia
- safety of atorvastatin simvastatin in patients